Across TCGA pan-cancer cohorts, CYP4F12 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYP4F12 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CYP4F12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP4F12 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC and HNSC are the cancer types where CYP4F12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.285	0.824	.038	4	view →
HNSC	DFS	Median	III,IV	0.787	0.564	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CYP4F12 tumor-vs-normal RNA expression · all CYP4F12 data types